Semaglutide is a long acting synthetic analogue of glucagon like peptide 1 (GLP-1) with a half-life of approximately 7 days. The longest active window among currently researched GLP-1 receptor agonist compounds achieved through fatty acid chain conjugation that enables albumin binding and protects against enzymatic degradation by dipeptidyl peptidase 4 (DPP-4). This formulation delivers 9.6mg total Semaglutide in a prefilled pen system at 2.4mg per dose, a high concentration, multi dose presentation providing four precisely measured administrations per pen in a ready to use format that eliminates reconstitution preparation steps.

Semaglutide’s pharmacological profile is defined by its exceptionally potent and sustained GLP-1 receptor activation relative to earlier GLP-1 agonist compounds. Its structural modifications including a C18 fatty diacid chain attached via a linker to lysine at position 26 produce a plasma half-life that supports once weekly administration while maintaining continuous GLP-1 receptor engagement between doses. This sustained receptor activation profile drives well documented downstream effects across glucose dependent insulin secretion, pancreatic glucagon suppression, gastric emptying delay, and hypothalamic appetite regulation through GLP-1 receptor populations in the arcuate nucleus and other satiety regulating brain regions. The combination of peripheral metabolic activity and central nervous system appetite modulation has made Semaglutide one of the most actively researched GLP-1 compounds in contemporary obesity, metabolic syndrome, and cardiovascular risk research.

Semaglutide holds regulatory approval in multiple jurisdictions under brand names for both type 2 diabetes and obesity indications. Contributing one of the most extensive human clinical literature bases of any GLP-1 receptor agonist compound, including landmark cardiovascular outcomes trial data. This clinical documentation depth distinguishes Semaglutide from most research peptide compounds in CSD’s range and positions it as a well characterized reference standard in comparative GLP-1 receptor agonist research. Within CSD’s incretin peptide family, Semaglutide’s pure GLP-1 receptor selectivity contrasts with the dual and triple receptor agonism of the GLP-2 TZ, GLP-2 TRZ, and GLP-3 RTA listings, making it a valuable single receptor reference compound in studies examining the isolated GLP-1 pathway contribution to the combined receptor responses of multi agonist formulations.

Every batch of CSD’s Semaglutide pen is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our GLP-1 and incretin agonist range represents the most comprehensive metabolic peptide sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside dual and triple incretin agonist compounds in comparative GLP-1 receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.